GCIV as an Adjuvant Therapy for Community-Acquired Severe Sepsis or Septic Shock
Status:
Terminated
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is to determine whether the intravenous application of 'Ⅳ-Globulin S inj. (Human
Immunoglobulin G)' can reduce mortality in patients with severe sepsis or septic shock.
Phase:
Phase 3
Details
Lead Sponsor:
Green Cross Corporation
Collaborator:
Symyoo
Treatments:
Antibodies Immunoglobulin G Immunoglobulins Immunoglobulins, Intravenous